“…In our experience, we have identified several patients carrying genetic VUS (missense, intronic, and silent variants) not only in main genes, MLH1 and MSH2 [ 80 ], but also in other MMR genes. According to international recommendations (Colon cancer Family Registry 2009, InSiGHT Variant Interpretation Committee 2011) we used a multifactorial likelihood model in an attempt to define a pathogenetic role for numerous VUS identified in MMR genes [ 50 , 51 , 64 , 85 ]. The segregation analysis, population studies (to exclude the polymorphic nature of the variant), assessment of MSI in tumor tissues, detection of loss of protein expression in tumor tissues by immunohistochemical analysis (IHC), in silico analysis by a variety of bioinformatics tools, and gene expression studies are strategies that have to be used to assess an exhaustive evaluation of the pathogenicity of uncertain variants [ 85 ].…”